BASKING RIDGE, N.J. & RAHWAY, N.J., April 3, 2024 - Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been.
Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the.
Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2 months seen with raludotatug deruxtecan in heavily pretreated patients Plans underway to initiate